Highlights
The PAMORA-RAP trial provides evidence for the first pharmacological intervention to prevent recurrent acute pancreatitis. Key highlights include:
- Naldemedine (0.2 mg daily) was associated with a 46% reduction in the risk of acute pancreatitis recurrence compared to placebo (HR 0.54; 95% CI, 0.29-1.01; p = 0.05).
- Participants who remained on treatment for at least one year experienced a statistically significant reduction in recurrence risk (HR 0.49; 95% CI, 0.24-0.97; p = 0.04).
- The treatment was safe and well-tolerated, with no significant differences in gastrointestinal adverse events or quality-of-life scores compared to the placebo group.
